Physician profile
Brian D Borsook
NPI 1437165370
$11,362.86
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,651 · 2020: $2,570 · 2021: $4,505 · 2022: $1,483 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,788.91 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $1,326.29 | 2021 | |
| Novo Nordisk INC | $824.25 | 2019-2022 | |
| Abbvie INC. | $789.09 | 2019-2022 | |
| Lilly USA, LLC | $555.99 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.64 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $499.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $494.86 | 2019-2022 | |
| Amgen INC. | $438.94 | 2019-2022 | |
| Pfizer INC. | $423.52 | 2019-2022 | |
| Amarin Pharma, INC. | $392.07 | 2019-2021 | |
| Astellas Pharma US INC | $348.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $266.99 | 2019-2021 | |
| Esperion Therapeutics, INC. | $239.81 | 2020-2024 | Nexletol, Nexlizet |
| Eisai INC. | $198.98 | 2020-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Borsook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.